INTRODUCTION
============

In 1987 \[[@R1]\], Marshall firstly described, the PFAPA (periodic fever, aphthous stomatitis, pharyngitis and adenitis) syndrome, which is characterized by recurrent episodes of fever associated with cervical adenitis, pharyngitis and aphthous stomatitis. The prognosis of this disease has been reported to be better than that of another autoinflammatory diseases \[[@R2]\]. Corticosteroids are effective in controlling episodes of illness in PFAPA, but they do not cure the ailments or prevent recurrence of the symptoms of this syndrome \[[@R3]\]. Interventions like tonsillectomy and administration of H~2~ blockers have been reported to be partially effective for prophylaxis \[[@R3]\]. However the complete pathogenesis of PFAPA is unknown yet, and hence the therapeutic regimens have not yet been established for PFAPA \[[@R4]\].

Familial Mediterranean fever (FMF) is a recessively inherited disorder characterized by acute attacks of fever, and serositis usually lasting for 1--3 days. FMF is caused by mutations in the ME diterranean FeVer gene (*MEFV),*which encodes the protein pyrin (marenostrin)1\[[@R5],[@R6]\]. Colchicine has been shown to be effective for prophylaxis in only 90% of the patients with FMF \[[@R7],[@R8]\].

Recent studies have described that heterozygous variants of the *MEFV* gene were found in patients with PFAPA \[[@R9]-[@R11]\]. However, it still remains unclear whether these variants are the causative factors of PFAPA.

The purpose of this study was to understand whether heterozygous variants of *MEFV* may be associated with the onset of PFAPA. We have also tried to understand whether these mutations act as accessory factors and modify the phenotype of patients with PFAPA.

PATIENTS AND METHODS
====================

Twenty children with frequent PFAPA episodes who visited our pediatric outpatient clinic were consecutively selected over a 5-year period (from January 2005 to January 2010). The diagnosis of PFAPA syndrome was established using previously established criteria \[[@R1],[@R3],[@R9]\]. These criteria include recurring fevers associated with exudative tonsillitis, negative throat culture, and possibly, aphthous stomatitis and cervical lymphadenopathy. The additional clinical criteria included completely asymptomatic intervals between the episodes, normal growth and development and exclusion of FMF, Behcet' s disease, and cyclic neutropenia. Oral low dose of prednisolone (0.3-0.5mg/kg/dose, 1 or 2 doses per day) was effective on all enrolled patients. *MEFV*, mevalonate kinase (*MVK*), and tumor necrosis factor receptor superfamily, member 1A (*TNFRSF1A*) genes of all enrolled patients were sequenced. After obtaining a written informed consent approved by the Institutional Review Board of Kyoto University, peripheral blood was collected from all patients, and, if needed, their family members. Genomic DNA was extracted, and all the exons including exon-intron junctions of the *MVK,* *MEFV,* and *TNFRSF1A* genes were amplified by polymerase chain reaction and then sequenced using the ABI3130.

The results are shown as a mean ± SD or proportion, as appropriate. Differences between the groups in discrete variables were evaluated using Fisher's exact test at 5% significance.

Two-sided *P* values were adjusted for multiplicity using Hochberg's method.

Comparisons of continuous variables were done using unpaired Student's *t*-test. All *P* values given are 2-sided. *P* values less than 0.05 were considered significant. Statistical calculation was conducted by SAS version 9.1.3.

RESULTS
=======

Twenty patients (9 boys, 11 girls) diagnosed with PFAPA were followed up in our clinic. Thirteen of these patients had a single *MEFV* (M^+^ group). No variant of *TNFRSF1A* and *MVK* was detected in all patients. The genotypes of the *MEFV* gene in the 13 patients are seen in Table **[1](#T1){ref-type="table"}**. The most common *MEFV* variant patterns seen were *E148Q-L110P* (5 patients) and*E148Q* (2 patients). One patient was homozygous of *E148Q* and heterozygous of*L110P*of*MEFV*. One patient was heterozygous of *E148Q-P369S-R408Q*. One patient was heterozygous for *E148Q-P369S-R408Q-E84K*. One patient had *E148Q-L110P-P369S-R408Q*. The minor variants,*P115R* and *R202Q*, were detected in 2 patients. More than 2 *MEFV variants* were on 1 allele in all PFAPA patients. In 7 patients, no *MEFV* mutations were found. The allele frequencies of *E148Q*, *L110P*, *P369S, R408Q* and G304R in 20 PFAPA patients were 0.3, 0.175, 0.075, 0.075 and 0, respectively (Table **[3](#T3){ref-type="table"}**).

Clinical and laboratory data were compared between *MEFV* positive group (n=13) and negative group (n=7) and are presented in Table **[2](#T2){ref-type="table"}**. Patients carrying an *MEFV* variant showed shorter duration of episodes of illness than patients without variants (3.6±0.86 days versus 5.3±1.89 days, *p*=0.0174). No significant differences in all other clinical and laboratory data were found between the 2 groups (Table **[2](#T2){ref-type="table"}**).

We also analyzed all sequences of *MEFV* genes in normal Japanese subjects (n=62). These individuals were healthy adult volunteers and had no recurrent episodes of fever. There was no difference in recruitment between the PFAPA patients and the control group. A comparison of these results between normal and PFAPA subjects is shown in Table **[3](#T3){ref-type="table"}**. In normal individuals, no significant allele frequencies were observed for the 4 variants found in PFAPA patients. In addition, the frequencies of *E148Q-L110P* and *P369S-R408Q*in the 2 groups were compared. A significant difference in the frequency of these variants was observed between the 2 groups (Table **[4](#T4){ref-type="table"}**, *p*= 0.043 and *p*= 0.026, respectively).

DISCUSSION
==========

We studied 20 patients with PFAPA who were diagnosed by Marshall criteria \[[@R1]\]. Our aim was to access the roles of the predominant variants in genes that cause other febrile illnesses like FMF, TNF receptor-associated periodic syndrome (TRAPS) and the MVK deficiency. We did not find any incidence of variants of TRAPS and MVK deficiency in PFAPA patients. However several heterogeneous variants of *MEFV* were detected in 13 out of 20 patients with PFAPA. We analyzed the frequency of the *E148Q-L110P*and*P369S-R408Q* variants in PFAPA and control subjects. Our analyses indicate that the incidence of these 2 variants is significantly higher in patients with PFAPA than in normal individuals.

Amongst autoinflammatory disease, only PFAPA syndrome has been described as a non-inherited syndrome, since familial inheritance has not been reported in previous studies \[[@R3],[@R12],[@R13]\]. However some studies have reported familial cases that included siblings or a sibling and the sibling's mother \[[@R14]-[@R16]\]. Therefore, the hereditary nature of this syndrome is still a matter of debate. With respect to the genetic factors that may cause the PFAPA syndrome, one study has strongly argued against the involvement of the *MEFV* gene \[[@R10]\], but another article \[[@R11]\] has shown that mutations of the *MEFV* genes were found in 27% of cases diagnosed with PFAPA syndrome on the basis of Marshall's clinical criteria. Our observations of the high frequency (65%) of *MEFV* variants are in agreement with that reported by Dagan \[[@R11]\]. The differences in the findings may be attributed to the ethnic differences between the individuals studied, the small sized of the study, and the study population that was selected.

The *L110P* variant, which is located in exon 2, was first reported in FMF patients in 2000 \[[@R17]\], and to date, several compound heterozygotes with other variants have been reported even in Japan \[[@R18],[@R19]\]. In contrast, although the role of the *E148Q* variant, which is located in exon 2, in FMF patients was controversial, a recent study concluded that the variant is just a benign polymorphism \[[@R20]\]. In a Japanese study \[[@R18]\] of FMF patients, the most frequently observed *MEFV* variants observed were *E148Q/M694I* (25.0%), *M694I* (17.5%), and *L110P/E148Q/M694I* (17.5%). However, no patients had the *M694V* variant. These patterns are quite different from those in Mediterranean patients with FMF. The study also reported that the allele frequencies of *E148Q*,*M694I*, and *L110P* were 0.44, 0.35, and 0.31, respectively, and that these frequencies were significant difference from those seen in healthy controls. In our study, the allele frequencies of *E148Q*, *L110P*, and*G304*were 0.3, 0.175, and 0, respectively, and these frequencies did not differ significantly between patients and healthy controls. No mutation at the *M694I* was detected in our cohorts of patients and controls. The allele frequency of *L110P* is higher in patients with PFAPA than in healthy controls; however, the difference is not significant. The frequency of the *E148Q-L110P* variant combination is significantly higher in the PFAPA group than in the healthy control group. If the*E148Q* variant is non-functional, the L110P variant may be associated with the onset of PFAPA syndrome.

In several types of inflammatory such as Behcet's disease \[[@R21]\], Crohn's disease \[[@R22]\], ulcerative colitis \[[@R23]\], Henoch-Schönlein purpura \[[@R24],[@R25]\] and the co-incidence of FMF variants has been investigated. These studies show increased incidence of genes involved in FMF in patients with these autoinflammatory diseases as well as the increased severity of the symptoms of each disease. On the other, in the patients with asthma, the incidence of FM mutation was decreased and the lower incidence correlated with reduced severity of symptoms \[[@R26]\]. Thus, FMF variants may affect the transition from Th2 to Th1 polarity in each disease. According to Berkun's study \[[@R27]\], PFAPA episodes in carriers of*MEFV* variants were shorter compared to those in patients without variants. In *MEFV* variant-positive patients, the regular cyclic pattern of attacks and the occurrence of oral aphthae was lower than those in patients without *MEFV* variants. In the present study, we found that the only affected variable was the duration of PFAPA episodes. Although no significant differences were observed in the regular cyclic pattern of attacks and the occurrence of oral aphthae between the 2 groups, the duration of PFAPA episodes was shorter in the variant-positive group than in the variant-negative group.

Taken together, these results show that the *MEFV* gene may not affect the onset of several autoinflammatory diseases, but is likely to modify the intensity and the displayed phenotype in terms of disease symptoms.

In conclusion, the *MEFV* variants, viz. *E148Q-L110P*, *P369-R408Q* may be associated with the onset of PFAPA, and some *MEFV* variants may affect the phenotype of PFAPA.
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###### 

The Genotypes of MEFV Genes of 13 Patients with PFAPA

  *MEFV* Variant               No. of Patients
  ---------------------------- -----------------
  *E148Q-L110P*                5
  *E148Q*                      2
  *E148Q-L110P/E148*           1
  *E148Q-P369S-R408Q*          1
  *E148Q-P369S-R408Q-E84K*     1
  *E148Q -L110P-P369S-R408Q*   1
  *R202Q*                      1
  *P115R*                      1

###### 

Clinical Characteristics of PFAPA Patients with Variants in the *MEFV* Gene Compared with those of PFAPA Patients without *MEFV* Variants

                                     Patients with *MEFV* Variants (n=13)   Patients without *MEFV* Variants (n=7)   *P* Value
  ---------------------------------- -------------------------------------- ---------------------------------------- ------------
  Age at onset (years)               2.8±1.9                                3.2±1.9                                  NS
  Age at Diagnosis (years)           4.3±2.2                                4.9±1.9                                  NS
  Male: female ratio                 5/8                                    4/3                                      NS
  Family history of PFAPA            4/9                                    3/4                                      NS
  Attack duration (days)             3.6±0.86                               5.3±1.89                                 *P*=0.0174
  Interval between attacks (weeks)   4.9±1.59                               5.5±0.96                                 NS
  Cyclic periodic attacks            5/13                                   4/7                                      NS
  Pharyngitis                        13/13                                  7/7                                      NS
  Aphthae                            7/13                                   5/7                                      NS
  Enlarged tonsillitis               13/13                                  7/7                                      NS
  Abdominal pains                    1/13                                   2/7                                      NS
  Musculoskeletal Pains              1/13                                   2/7                                      NS
  Headaches                          4/13                                   5/7                                      NS
  WBC/μL                             143±41                                 142±41                                   NS
  ESR mm/h                           87±23                                  72±14                                    NS
  CRP levels mg/dL                   6.52±3.53                              5.87±2.85                                NS

NS: not significant.

###### 

Allele Frequencies of MEFV Variants in PFAPA Subjects and Normal Unaffected Subjects

  Variant   PFAPA Subjects (n=40)   Unaffected Subjects (n=124)   *P* Value
  --------- ----------------------- ----------------------------- -----------
  *E148Q*   30.0%                   18.5%                         NS
  *L110P*   17.5%                   6.5%                          NS
  *G304R*   0.0%                    3.2%                          NS

NS: not significant.

###### 

Frequencies of *MEFV* Variants in PFAPA Subjects and Normal Unaffected Subjects

  Variant         PFAPA Subjects (n=20)   Unaffected Subjects (n=62)   *P* Value
  --------------- ----------------------- ---------------------------- -----------
  *E148Q-L110P*   35%                     13%                          *P*=0.043
